Safety and Performance of a Fetal Monitoring System

NCT ID: NCT05294211

Last Updated: 2024-05-23

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

120 participants

Study Classification

INTERVENTIONAL

Study Start Date

2022-08-31

Study Completion Date

2023-01-24

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The objective of this study is to demonstrate the safety and performance of the M•care™ System for use in antenatal monitoring of pregnant women ≥ 32 weeks' gestation.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Pregnancy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

OTHER

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

M•care™ System + CTG

The M•care System and standard of care CTG (cardiotocography) will be applied for fetal and maternal monitoring

Group Type EXPERIMENTAL

M•care™ System

Intervention Type DEVICE

The M•care™ System will be applied for monitoring of fetal heart rate (FHR), maternal heart rate (MHR) and uterine activity (UA)

Cardiotocography (CTG)

Intervention Type DEVICE

A standard of care CTG device will be applied for monitoring of fetal heart rate (FHR), maternal heart rate (MHR) and uterine activity (UA)

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

M•care™ System

The M•care™ System will be applied for monitoring of fetal heart rate (FHR), maternal heart rate (MHR) and uterine activity (UA)

Intervention Type DEVICE

Cardiotocography (CTG)

A standard of care CTG device will be applied for monitoring of fetal heart rate (FHR), maternal heart rate (MHR) and uterine activity (UA)

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Able to provide informed consent and follow study instructions
* 18 years of age or older
* Pregnant subjects ≥ 32 weeks' gestation
* Singleton pregnancy
* BMI ≥15, pre-pregnancy
* BMI ≤45, pre-pregnancy
* Belly circumference ≥80 cm and ≤ 130 cm

Exclusion Criteria

* Known major fetal malformation or chromosome abnormality
* Abdominal medical skin conditions, including surgical incisions, open wounds with our without infections, edema, or irritation
* Participants with implanted electronic devices (pacemakers, defibrillator, etc.)
* Involvement in another clinical trial currently or previously in this pregnancy that, in the investigator's opinion, would affect the conduct of this study
* Medical or obstetric problem that in the investigator's opinion would make the participant incapable of taking part in the study
* In the investigator's opinion, the participant is not likely to be available for the minimum 60 minutes of the monitoring session
* History of skin allergies to cosmetics and lotions
* Known allergies to silver, nylon, or polyester
Minimum Eligible Age

18 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Marani Health

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

NorthShore University Health System

Evanston, Illinois, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Provided Documents

Download supplemental materials such as informed consent forms, study protocols, or participant manuals.

Document Type: Study Protocol and Statistical Analysis Plan

View Document

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

MH-001

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

nuMoM2b Heart Health Study
NCT02231398 COMPLETED